Gene editing, cell therapies, and RNA-based platforms have changed the way we think about treating diseases, particularly for patients living with rare diseases who had limited or few options. The science behind genomic medicine has progressed rapidly over the last two decades. However, the industry continues to struggle with how to expand these medicines into complex new indications and how to manufacture these life-changing therapeutics affordably at scale.
The operational constraints facing drug manufacturers today are rampant. They show up as long development timelines, fragile and complex manufacturing processes, limited capacity, talent gaps, fragmented data, and regulatory uncertainty. Solving those problems requires collaboration – applied earlier, more deliberately, and more systematically than we as an industry have ever done.
The limits of going it alone
Genomic medicines are very different from conventional therapeutics. Some are individualized while others are developed to treat diverse populations. Most are acutely sensitive to process changes – early decisions around process design, vectors, formulations, or analytics can dramatically affect scalability, cost, and quality later.
This interconnectedness exposes the limits of operating in silos. Academic researchers, biotech innovators, manufacturers, technology developers, and regulators each see different parts of the same system. When those perspectives remain disconnected, bottlenecks often emerge late in the process when they are most difficult to solve.
No single organization has all the capabilities required to develop, industrialize, and deliver genomic medicines at scale. That is not a failure of ambition, but the reality of working at the edge of biology, engineering, and data science. The question is not whether collaboration is necessary, but how we use it most effectively to accelerate the development of advanced therapeutics.
Across biopharma, one pattern is increasingly hard to ignore: regions and organizations that coordinate strengths across R&D, manufacturing, talent, policy, and supply chains tend to deliver therapies faster and with greater resilience.
Advanced modalities put simultaneous pressure on infrastructure, workforce skills, regulatory pathways, digital maturity, and manufacturing agility. Improving one element in isolation will not help. Progress instead depends on how well these elements reinforce one another.
Translation improves when collaboration starts earlier
One of the persistent challenges in advanced therapies is discovering constraints too late. A therapy that looks promising in preclinical or early clinical work can stall when manufacturing proves too variable, analytics too immature, or regulatory expectations unclear.
However, when developers engage manufacturing experts, technology providers, and regulatory partners sooner, translation becomes more intentional. Processes are designed with scale in mind; automation and standardization are planned, not retrofitted; and analytics and evidence packages evolve alongside programs rather than being assembled at the end.
This approach is particularly critical for smaller biotech companies, which drive much of the innovation in genomic medicine but cannot build end-to-end infrastructure on their own. Through collaboration, these teams can remain focused on biology and patient impact while accessing the platforms and expertise needed to move swiftly toward commercialization.
Scale depends on shared standards
Manufacturing remains one of the biggest barriers to broader access, particularly for cell and gene therapies. Bespoke processes, manual workflows, and inconsistent analytics drive cost and limit throughput. As an industry, we talk about automation and standardization, but achieving them in practice requires coordination.
Shared standards require collaboration across therapy developers, manufacturers, technology partners, and regulators. Often, that collaboration needs to happen in pre‑competitive settings, where foundational challenges can be solved once rather than repeatedly.
Standardization is sometimes viewed as a constraint on innovation. In reality, it enables innovation by stabilizing the parts of the process that should be repeatable, freeing teams to focus on differentiating technology and improving therapeutic performance and patient outcomes.
Regulators must be engaged as partners
For advanced therapies, engagement with regulators early is critical to success. Many genomic modalities do not fit neatly into legacy frameworks, or may qualify for specialized pathways, and late engagement can lead to avoidable delays.
Early, constructive collaboration with regulators, such as sharing data, aligning on evidence, and building understanding gradually, reduces uncertainty. It also helps establish standard processes that benefit future programs, not just individual assets.
When industry engages regulators thoughtfully and consistently, the development pathway becomes clearer and more predictable.
Resilience and sustainability require shared responsibility
Genomic medicines depend on complex global supply chains and specialized inputs. Disruption, whether operational or environmental, can have immediate patient impact. Building resilience requires coordination across suppliers, manufacturers, and logistics partners.
Sustainability adds another layer. As advanced therapies scale, so does their environmental footprint. Reducing emissions, waste, and resource intensity across the value chain is not something any one organization can accomplish alone. It requires collaboration that aligns long-term performance with near-term decision making.
Resilient and sustainable systems are not only better for society, they are more reliable, more predictable, and better suited to supporting global patient access for genomic medicines.
Making collaboration intentional, not reactive
If genomic medicine is to fulfill its promise, collaboration must be embedded in development strategies, manufacturing models, digital architectures, and regulatory engagement.
Whether patients benefit at scale will depend on how effectively we work together. Acceleration will not come from moving faster alone, but from aligning earlier, sharing intelligently, and building systems designed to scale.
That is the work ahead and it is work none of us can do in isolation.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
